Patents by Inventor Anna Teresa Palamara

Anna Teresa Palamara has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 8785493
    Abstract: Activation of HIV-1 replication causes oxidative stress, which in turn potentiates HIV-1 replication. The common basis for the compounds of the present invention is: A) the capacity of reactivating HIV-1 from latency, and B) the ability to counteract the cellular machinery which activates in order to limit the effects of oxidative stress. In this way, oxidative stress can be potentiated and a “chain reaction” is sparked. This “chain reaction” induces a more efficient reactivation of HIV-1 from latency and, in some cases, induces selective killing of the infected cells. Actions A) and B) can either be carried out by one drug exerting both effects, or obtained by the combined use of distinct drugs. There are two main cellular machineries counteracting oxidative stress, i.e. the thioredoxin (Trx) thioredoxin reductase (TrxR) system and glutathione. Herein, we present drug strategies capable of exerting action B) by blocking either of the two machineries.
    Type: Grant
    Filed: October 29, 2009
    Date of Patent: July 22, 2014
    Assignee: Istituto Superiore di Sanita
    Inventors: Andrea Savarino, Antonello Mai, Anna Teresa Palamara, Enrico Garaci
  • Patent number: 8431617
    Abstract: The use of resveratrol is described fir the preparation of a medicament for the treatment of influenza. Said medicament exerts itself in therapeutic activity through inhibition of viral replication.
    Type: Grant
    Filed: October 14, 2003
    Date of Patent: April 30, 2013
    Assignee: Sigma-Tau Industrie Farmaceutiche Riunite S.p.A.
    Inventors: Enrico Garaci, Anna Teresa Palamara
  • Publication number: 20110305774
    Abstract: Activation of HIV-1 replication causes oxidative stress, which in turn potentiates HIV-1 replication. The common basis for the compounds of the present invention is: A) the capacity of reactivating HIV-1 from latency, and B) the ability to counteract the cellular machinery which activates in order to limit the effects of oxidative stress. In this way, oxidative stress can be potentiated and a “chain reaction” is sparked. This “chain reaction” induces a more efficient reactivation of HIV-1 from latency and, in some cases, induces selective killing of the infected cells. Actions A) and B) can either be carried out by one drug exerting both effects, or obtained by the combined use of distinct drugs. There are two main cellular machineries counteracting oxidative stress, i.e. the thioredoxin (Trx) thioredoxin reductase (TrxR) system and glutathione. Herein, we present drug strategies capable of exerting action B) by blocking either of the two machineries.
    Type: Application
    Filed: October 29, 2009
    Publication date: December 15, 2011
    Applicant: ISTITUTO SUPERIORE DI SANITA
    Inventors: Andrea Savarino, Marina Lusic, Antonello Mai, Anna Teresa Palamara, Enrico Garaci